[go: up one dir, main page]

MX2009005508A - Pirimidinas substituidas y su uso como moduladores de cinasas c-jun n-terminales. - Google Patents

Pirimidinas substituidas y su uso como moduladores de cinasas c-jun n-terminales.

Info

Publication number
MX2009005508A
MX2009005508A MX2009005508A MX2009005508A MX2009005508A MX 2009005508 A MX2009005508 A MX 2009005508A MX 2009005508 A MX2009005508 A MX 2009005508A MX 2009005508 A MX2009005508 A MX 2009005508A MX 2009005508 A MX2009005508 A MX 2009005508A
Authority
MX
Mexico
Prior art keywords
sup
substituted pyrimidines
jnk modulators
jnk
modulators
Prior art date
Application number
MX2009005508A
Other languages
English (en)
Inventor
James Patrick Dunn
David Michael Goldstein
Achyutharao Sidduri
Wylie Solang Palmer
Joan Heather Hogg
Leyi Gong
Christophe Michoud
Teresa Alejandra Trejo-Martin
Tania Silva
Parcharee Tivitmahaisoon
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39099641&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2009005508(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2009005508A publication Critical patent/MX2009005508A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La invención se refiere a nuevos compuestos moduladores de la JNK, de la fórmula (I) (ver fórmula (I)) en donde X1, X2, X3, X4, X5, X6, R, R1, Z y n tienen los significados definidos en la descripción y en las reivindicaciones, así como las sales fisiológicamente aceptables de los mismos.
MX2009005508A 2006-12-08 2007-11-28 Pirimidinas substituidas y su uso como moduladores de cinasas c-jun n-terminales. MX2009005508A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87362506P 2006-12-08 2006-12-08
PCT/EP2007/062920 WO2008068171A1 (en) 2006-12-08 2007-11-28 Substituted pyrimidines and their use as jnk modulators

Publications (1)

Publication Number Publication Date
MX2009005508A true MX2009005508A (es) 2009-06-03

Family

ID=39099641

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009005508A MX2009005508A (es) 2006-12-08 2007-11-28 Pirimidinas substituidas y su uso como moduladores de cinasas c-jun n-terminales.

Country Status (18)

Country Link
US (1) US8399462B2 (es)
EP (1) EP2102194A1 (es)
JP (1) JP5179509B2 (es)
KR (1) KR101152162B1 (es)
CN (1) CN101547917A (es)
AR (1) AR064133A1 (es)
AU (1) AU2007328981B2 (es)
BR (1) BRPI0720003A2 (es)
CA (1) CA2670375A1 (es)
CL (1) CL2007003502A1 (es)
IL (1) IL198543A0 (es)
MX (1) MX2009005508A (es)
NO (1) NO20091942L (es)
PE (1) PE20081507A1 (es)
RU (1) RU2493155C2 (es)
TW (1) TW200831101A (es)
WO (1) WO2008068171A1 (es)
ZA (1) ZA200903495B (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008151992A2 (en) * 2007-06-15 2008-12-18 F. Hoffmann-La Roche Ag A novel process for the preparation of 3-amino-pentan-1,5-diol
CA2701275C (en) * 2007-10-23 2016-06-21 F. Hoffmann-La Roche Ag Kinase inhibitors
RU2504545C2 (ru) * 2008-05-16 2014-01-20 Ф. Хоффманн-Ля Рош Аг Ингибиторы jnk
CN102256965A (zh) 2008-12-19 2011-11-23 霍夫曼-拉罗奇有限公司 嘧啶-2-基氨基衍生物和它们治疗炎症的用途
CA2749236A1 (en) 2009-02-24 2010-09-02 F. Hoffmann-La Roche Ag Imidazo [1,2-a] pyridines as jnk modulators
EP2440058A4 (en) 2009-06-12 2012-11-21 Dana Farber Cancer Inst Inc MELTED HETEROCYCLIC COMPOUNDS AND APPLICATIONS THEREOF
AU2010283769B2 (en) * 2009-08-10 2015-09-17 F. Hoffmann-La Roche Ag Inhibitors of JNK
WO2011060295A1 (en) * 2009-11-13 2011-05-19 Genosco Kinase inhibitors
CA2784807C (en) 2009-12-29 2021-12-14 Dana-Farber Cancer Institute, Inc. Type ii raf kinase inhibitors
CN102918035B (zh) * 2010-06-04 2015-05-27 霍夫曼-拉罗奇有限公司 用作jnk的抑制剂的2-氨基-嘧啶衍生物
RU2012155144A (ru) * 2010-06-04 2014-07-20 Ф. Хоффманн-Ля Рош Аг Ингибиторы jnk
US9139590B2 (en) 2011-02-04 2015-09-22 Duquesne University Of The Holy Spirit Bicyclic and tricyclic pyrimidine tyrosine kinase inhibitors with antitubulin activity and methods of treating a patient
KR101779644B1 (ko) 2011-03-10 2017-09-18 다이이찌 산쿄 가부시키가이샤 디스피로피롤리딘 유도체
WO2013074986A1 (en) 2011-11-17 2013-05-23 Dana-Farber Cancer Institute, Inc. Inhibitors of c-jun-n-terminal kinase (jnk)
RU2641916C2 (ru) 2012-10-02 2018-01-23 Байер Кропсайенс Аг Гетероциклические соединения в качестве пестицидов
US10112927B2 (en) 2012-10-18 2018-10-30 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
US10000483B2 (en) 2012-10-19 2018-06-19 Dana-Farber Cancer Institute, Inc. Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof
US9758522B2 (en) 2012-10-19 2017-09-12 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
WO2014134772A1 (en) * 2013-03-04 2014-09-12 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
WO2014134776A1 (en) 2013-03-04 2014-09-12 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
WO2014134774A1 (en) * 2013-03-04 2014-09-12 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
EP2964221B1 (en) 2013-03-04 2017-12-06 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
JP6491202B2 (ja) 2013-10-18 2019-03-27 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド サイクリン依存性キナーゼ７（ｃｄｋ７）の多環阻害剤
CA2927917C (en) 2013-10-18 2022-08-09 Syros Pharmaceuticals, Inc. Heteroaromatic compounds useful for the treatment of proliferative diseases
EP3068389B1 (en) * 2013-11-14 2019-10-02 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
EP3489232A3 (en) 2014-04-04 2019-07-31 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
US10017477B2 (en) 2014-04-23 2018-07-10 Dana-Farber Cancer Institute, Inc. Janus kinase inhibitors and uses thereof
US9862688B2 (en) 2014-04-23 2018-01-09 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged janus kinase inhibitors and uses thereof
WO2016036586A1 (en) 2014-09-03 2016-03-10 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
WO2016094821A2 (en) * 2014-12-11 2016-06-16 Beta Pharma, Inc. Substituted 2-anilinopyrimidine derivatives as egfr modulators
EP3236959B1 (en) 2014-12-23 2025-09-24 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
CA2978518C (en) 2015-03-27 2023-11-21 Nathanael S. Gray Inhibitors of cyclin-dependent kinases
CA2986441A1 (en) 2015-06-12 2016-12-15 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
JP7028766B2 (ja) 2015-09-09 2022-03-02 ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド サイクリン依存性キナーゼの阻害剤
WO2017133658A1 (en) * 2016-02-05 2017-08-10 Savira Pharmaceuticals Gmbh 4, 7-diazaindole and 4, 7-diazaindazole derivatives and their use in the treatment, amelioration or prevention of influenza
WO2017133664A1 (en) * 2016-02-05 2017-08-10 Savira Pharmaceuticals Gmbh Bicyclic pyridine and pyrimidine derivatives and their use in the treatment， amelioration or prevention of influenza
TW201904577A (zh) 2017-06-16 2019-02-01 美商貝達醫藥公司 N-(2-(2-二甲胺基)乙氧基)-4-甲氧基-5-((4-(1-甲基-1h-吲哚-3-基)嘧啶-2-基)胺基)苯基)丙烯醯胺及其鹽之醫藥調配物
KR20190043437A (ko) 2017-10-18 2019-04-26 씨제이헬스케어 주식회사 단백질 키나제 억제제로서의 헤테로고리 화합물
WO2020005807A1 (en) 2018-06-25 2020-01-02 Dana-Farber Cancer Institute, Inc. Taire family kinase inhibitors and uses thereof
KR102195348B1 (ko) 2018-11-15 2020-12-24 에이치케이이노엔 주식회사 단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물
EP3902542A4 (en) 2018-12-28 2022-09-07 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 and uses thereof
EP4155308A4 (en) * 2020-07-14 2024-04-17 Wuhan LL Science and Technology Development Co., Ltd. ROCK INHIBITOR AND PRODUCTION PROCESS AND USE THEREOF
CN113563310B (zh) * 2021-06-25 2022-10-11 浙江工业大学 一种4-(1-甲基吲哚-3-基)嘧啶类衍生物及其应用
WO2023107705A1 (en) 2021-12-10 2023-06-15 Incyte Corporation Bicyclic amines as cdk12 inhibitors
CN114790174B (zh) * 2022-04-14 2023-09-29 淮阴工学院 一种连续合成1h-吲唑类化合物的方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4788195A (en) * 1986-01-13 1988-11-29 American Cyanamid Company 4,5,6-substituted-N-(substituted-phenyl)-2-pyrimidinamines
EP1206265B1 (en) 1999-06-30 2003-11-12 Merck & Co., Inc. Src kinase inhibitor compounds
GB9919778D0 (en) * 1999-08-21 1999-10-27 Zeneca Ltd Chemical compounds
AU2001237041B9 (en) * 2000-02-17 2005-07-28 Amgen Inc. Kinase inhibitors
CN1438890A (zh) * 2000-02-25 2003-08-27 弗·哈夫曼-拉罗切有限公司 腺苷受体调制剂
GB0103926D0 (en) * 2001-02-17 2001-04-04 Astrazeneca Ab Chemical compounds
ATE416175T1 (de) * 2001-02-20 2008-12-15 Astrazeneca Ab 2-arylaminopyrimidine zur behandlung von mit gsk3 in zusammenhang stehenden erkrankungen
HUP0303258A3 (en) * 2001-02-23 2004-06-28 Merck & Co Inc N-substituted nonaryl-heterocyclic nmda/nr2b antagonists and pharmaceutical compositions containing them
US20040171630A1 (en) * 2001-06-19 2004-09-02 Yuntae Kim Tyrosine kinase inhibitors
ES2262899T3 (es) * 2001-12-17 2006-12-01 Smithkline Beecham Corporation Derivados de pirazolopiridazina.
TW200302722A (en) 2002-02-13 2003-08-16 Astrazeneca Ab Therapeutic agents
CA2491895C (en) 2002-07-09 2011-01-18 Vertex Pharmaceuticals Incorporated Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
TW200528101A (en) 2004-02-03 2005-09-01 Astrazeneca Ab Chemical compounds
WO2006050076A1 (en) * 2004-10-29 2006-05-11 Janssen Pharmaceutica, N.V. Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders
PL1896470T3 (pl) * 2005-05-16 2011-03-31 Irm Llc Pochodne pirolopirydynowe jako inhibitory kinazy białkowej
DE102006012617A1 (de) * 2006-03-20 2007-09-27 Merck Patent Gmbh 4-(Pyrrolopyridinyl)-pyrimidinyl-2-amin-derivate
EP2066319B1 (en) 2006-09-08 2012-02-01 F. Hoffmann-La Roche AG Benzotriazole kinase modulators
CN103739595A (zh) 2006-10-02 2014-04-23 Irm责任有限公司 作为蛋白激酶抑制剂的化合物和组合物
CA2675511A1 (en) 2006-10-10 2008-04-17 Amgen Inc. N-aryl pyrazole compounds for use against diabetes
CN102256965A (zh) * 2008-12-19 2011-11-23 霍夫曼-拉罗奇有限公司 嘧啶-2-基氨基衍生物和它们治疗炎症的用途

Also Published As

Publication number Publication date
AR064133A1 (es) 2009-03-11
RU2493155C2 (ru) 2013-09-20
JP2010511655A (ja) 2010-04-15
WO2008068171A1 (en) 2008-06-12
WO2008068171A9 (en) 2009-07-16
KR101152162B1 (ko) 2012-07-10
PE20081507A1 (es) 2008-11-12
TW200831101A (en) 2008-08-01
NO20091942L (no) 2009-07-07
EP2102194A1 (en) 2009-09-23
CN101547917A (zh) 2009-09-30
AU2007328981A1 (en) 2008-06-12
KR20090075877A (ko) 2009-07-09
JP5179509B2 (ja) 2013-04-10
BRPI0720003A2 (pt) 2018-09-18
IL198543A0 (en) 2010-02-17
AU2007328981B2 (en) 2013-07-11
ZA200903495B (en) 2010-04-28
RU2009125672A (ru) 2011-01-20
US20080146565A1 (en) 2008-06-19
CL2007003502A1 (es) 2008-06-27
US8399462B2 (en) 2013-03-19
CA2670375A1 (en) 2008-06-12

Similar Documents

Publication Publication Date Title
MX2009005508A (es) Pirimidinas substituidas y su uso como moduladores de cinasas c-jun n-terminales.
MX2009002229A (es) Benzotriazoles como moduladores de cinasas.
ECSP099413A (es) COMPUESTOS A BASE DE 4 - fenil - 6 - (2,2,2 - trifluoro - 1 - feniletoxi)pirimidina Y MÉTODOS PARA SU EMPLEO
MX2007005408A (es) Compuestos de aminoquinazolinas.
SE0401971D0 (sv) Piperidne derivatives
NO20083694L (no) Bruk av rylener som markorer for vaesker
TW200833324A (en) Sulfonamide derivatives
UA87153C2 (ru) Энантиомерно чистые аминогетероарильные соединения как ингибиторы протеинкиназы
MY169515A (en) Quinazolinedione derivatives as parp inhibitors
TW200610531A (en) Phthalazine derivatives as PARP inhibitors
MX2009008798A (es) Derivados de iminipiridina y sus usos como microbicidas.
MY134568A (en) Cb2 receptor agonists
MX2010006143A (es) Azolilmetiloxiranos, su uso y agentes que lo contienen.
MX2007005933A (es) Compuestos de acetamida como fungicidas.
MX2007011023A (es) 2-(4-oxo-4h-quinazolin-3-il) acetamidas y su uso como antagonistas de vasopresin v3.
SE0401970D0 (sv) Novel compounds
ZA200701137B (en) Triazolophthalazines
TW200716628A (en) Novel compounds
MX2010010406A (es) Tetrahidrofenantridinonas y tetrahidrociclopentaquinolinonas como inhibidores de la polimerizacion de poli(adp-ribosa)polimerasa-1 y tubulina.
TW200732303A (en) Novel fused pyrrole derivatives
MX2007014405A (es) Novedosos derivados de oxadiazol y su uso como moduladores aloestericos positivos de los receptores de glutamato metabotropicos.
ATE477256T1 (de) Thienylverbindungen
IL200469A0 (en) Benzimidazole derivatives
TW200600499A (en) Novel amido-substituted hydroxy-6-phenylphenanthridines
MXPA05009282A (es) Derivados de anilina sustituidos.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal